Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Other Operating Expenses (2016 - 2021)

Anika Therapeutics (ANIK) has disclosed Other Operating Expenses for 13 consecutive years, with $10.0 million as the latest value for Q3 2024.

  • On a quarterly basis, Other Operating Expenses changed N/A to $10.0 million in Q3 2024 year-over-year; TTM through Jun 2025 was $10.0 million, a 137.96% increase, with the full-year FY2021 number at -$21.1 million, up 8.22% from a year prior.
  • Other Operating Expenses was $10.0 million for Q3 2024 at Anika Therapeutics, up from $4.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $10.0 million in Q3 2024 to a low of -$15.7 million in Q4 2020.
  • A 3-year average of -$208400.0 and a median of $1.8 million in 2021 define the central range for Other Operating Expenses.
  • Biggest YoY gain for Other Operating Expenses was 30763.64% in 2020; the steepest drop was 447.41% in 2020.
  • Anika Therapeutics' Other Operating Expenses stood at -$15.7 million in 2020, then surged by 105.27% to $825000.0 in 2021, then surged by 1108.24% to $10.0 million in 2024.
  • Per Business Quant, the three most recent readings for ANIK's Other Operating Expenses are $10.0 million (Q3 2024), $4.2 million (Q2 2024), and $825000.0 (Q4 2021).